EUCTR2008-005625-11-DE进行中（未招募）不适用
A multi-center, double-blind, double-dummy, randomized, controlled, parallel-group study to assess efficacy and safety of SH T00658ID compared to SH D593B in the treatment of primary dysmenorrhea - Effect on primary dysmenorrhea
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 580
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Signed and dated informed consent of subject. If legally required, signed and dated informed consent from parent or legal representative for subjects considered minors by local legislation.
- •2. Otherwise healthy female subjects requesting contraception and suffering from primary dysmenorrhea with a sum score for dysmenorrheic pain intensity of = 8 over 2 baseline cycles documented by a prospective self-rated sum pain score
- •3. Age: 14 – 50 years (inclusive; smokers must not be older than 35 years) at the time point of informed consent
- •4. Normal cervical smear not requiring further follow-up (a cervical smear has to be taken at the screening visit, or a normal result has to be available that was documented within the last 6 months before the screening visit)
- •5. Women with cyclic menstrual bleeding, defined by a cycle length between 25 and 35 days and no amenorrheic cycles or cycles without withdrawal bleeding during the last 3 months prior to visit 1.
- •6. Able to tolerate ibuprofen and willing to use only ibuprofen supplied for the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnancy or lactation (delivery, abortion, or lactation within three cycles before the start of treatment)
- •2. Obesity: body mass index (BMI) > 32 kg/m2
- •3. Hypersensitivity to any of the study drug ingredients
- •4. Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication (such as but not limited to duodenal ulcers, gastritis, gastrectomy or gastric resection surgery, or renal compromise)
- •5. Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results
- •6. Any disease or condition that may worsen under hormonal treatment such as: See Section 4.1.2 of the Protocol for details.
- •7. Undiagnosed abnormal genital bleeding
- •8. Abuse of alcohol, drugs, or medicines (e.g. laxatives)
- •9. Other contraceptive methods:
- •sterilization
- •oral, vaginal or transdermal hormonal contraception during treatment
- •intra-uterine devices (IUD) with or without hormone release still in place within
- •30 days of visit 1
- •implants/depots still in place within 30 days of visit 1
- •long acting preparations (e.g. depot medroxyprogesterone acetate, monthly
- •contraceptive injection) within a period of three times the injection interval before
- •start of treatment.
- •10. Any medication that could result in excessive accumulation, impaired metabolism, or altered excretion of the study drug or interfere with the conduct of the study or the interpretation of the results such as:
- •products containing St. John’s wort (Hypericum perforatum) within 28 days
- •before start of treatment
- •antibiotics within 9 days before start of treatment
- •anticoagulants (e.g. heparin, coumarin) within 28 days before start of treatment
- •antiepileptics (hydantoin derivatives [e.g. phenytoin] or carboxamide derivatives
- •[e.g. carbamazepine, oxcarbamazepine], others [e.g. felbamate, topiramate,
- •keppra, zonisamide, lamotrigine]) within 28 days before start of treatment
- •hypnotics and sedatives (e.g. barbiturate derivatives, primidone) within 28 days
- •before start of treatment
- •tuberculostatics (e.g. rifampicin) within 28 days before start of treatment
- •oral antimycotics (e.g. griseofulvin, ketoconazole, itraconazole, fluoconazole)
- •within 28 days before start of treatment (no wash-out period necessary for single
- •shot treatment)
- •virostatic agents (except for topical use, e.g. ritonavir) within 28 days before start
- •of treatment
- •phenylbutazone within 28 days before start of treatment
- •additional sex steroids and other drugs impairing ovarian function within 28 days
- •before start of treatment (for exceptions, long acting drugs and contraceptives
- •refer to exclusion criterion 10).
- •- Gonadotropin releasing hormone (GnRH) analogue 3 months depot
- •within 6 months before start of treatment
- •- GnRH analogue 1 month depot within 3 months before start of treatment
- •11. Simultaneous participation in another clinical trial or participation in another clinical trial prior to study entry that might have an impact on the study objectives at the discretion of the investigator
- •12. Major surgery scheduled for the study period
- •13. Subject is a dependent person, e.g. a family member or member of the investigator’s staff
- •14. Inability to cooperate with the study procedures for any reason, including the following examples: language comprehension, psychiatric illness, inability to get to the study site.
研究者
相似试验
进行中（未招募）
不适用
A multi-center, double-blind, double-dummy, randomized, controlled, parallel-group study to assess efficacy and safety of SH T00658ID compared to SH D593B in the treatment of primary dysmenorrhea - NDThe primary objective of this study is to show superiority of SH T00658ID over SH D593B with respect to the number of days with dysmenorrheic pain in a defined period, i.e. comparison between two baseline cycles and two treatment cycles.MedDRA version: 9.1Level: LLTClassification code 10030970Term: Oral contraceptionEUCTR2008-005625-11-ITBayer Healthcare AG580
进行中（未招募）
不适用
ot applicableEUCTR2010-022971-79-PLHelsinn Healthcare SA660
进行中（未招募）
不适用
A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric PatientsEvaluate the efficacy of a single palonosetron IV dose to prevent postoperative nausea and vomiting through 24 hours.Evaluate the safety and tolerability of IV palonosetron in pediatric patients.MedDRA version: 13.1Level: LLTClassification code 10036238Term: Postoperative vomitingSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 13.1Level: LLTClassification code 10036285Term: Postoperative nauseaSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2010-022971-79-HUHelsinn Healthcare SA660
进行中（未招募）
不适用
ot applicablePostoperative nausea and vomiting (PONV)MedDRA version: 14.0Level: LLTClassification code 10036238Term: Postoperative vomitingSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 14.0Level: LLTClassification code 10036285Term: Postoperative nauseaSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2010-022971-79-CZHelsinn Healthcare SA660
进行中（未招募）
不适用
A randomized, blinded, double-dummy, multi-center, placebo controlled, 3 period, cross-over study to assess the effect of QVA149 (110/50 µg o.d.) on exercise endurance in patients with moderate to severe chronic obstructive pulmonary disease (COPD), using tiotropium as an active control - n/aEUCTR2010-022721-14-DEovartis Pharma Services AG80